LEADER 04052nam  2201285z- 450 
001 9910557349203321
005 20231214132942.0
035   $a(CKB)5400000000042398
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/77108
035   $a(EXLCZ)995400000000042398
100   $a20202201d2021      |y             0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aCancer Immunology
210   $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021
215   $a1 electronic resource (316 p.)
311   $a3-0365-2573-4 
311   $a3-0365-2572-6 
330   $aThe past decade has seen immunotherapy rise to the forefront of cancer treatment. This Special Issue of Cancers aims to elaborate on the latest developments, cutting-edge technologies, and prospects in cancer immunology and immunotherapy. Seventeen exceptional studies, including original contributions and review articles, written by international scientists and physicians, primarily concerning the fields of tumor biology, cancer immunology, therapeutics, and drug development, comprise the main body of this Special Issue.
606   $aMedicine$2bicssc
610   $aNKG2D
610   $aCAR T
610   $aIL-7
610   $aprostate cancer
610   $acell therapy
610   $aCD19-CAR-T
610   $aB cell aplasia
610   $aKIR
610   $aPD-1
610   $ainhibitory CAR
610   $atumor-infiltrating lymphocytes
610   $atumor microenvironment
610   $aimmunotherapy
610   $aNK cells
610   $acancer stem cells (CSCs)
610   $aantibody-dependent cellular cytotoxicity (ADCC)
610   $adifferentiation
610   $acytotoxicity
610   $aIFN-?
610   $aosteoclasts
610   $aMICA/B mAb
610   $aDNA methylation
610   $aRNA methylation
610   $aS-adenosylmethionine (SAM)
610   $acancer
610   $ainnate immunity
610   $aadaptive immunity
610   $aT cells
610   $am6A
610   $aPD-L1
610   $aresistance
610   $aimmune checkpoints
610   $acancer vaccine
610   $acombination immunotherapy
610   $aTCR diversity
610   $aorgan transplantation
610   $acarcinoma
610   $aepidemiologic studies
610   $aimmunosuppression
610   $aCTLA-4
610   $aTreg cells
610   $aimmune checkpoint inhibitors
610   $aCD28
610   $aantigen-presenting cells
610   $aIL15
610   $acolon cancer
610   $amelanoma
610   $auveal
610   $aBAP1
610   $aanti-PD-1
610   $aanti-CTLA-4
610   $aTIL
610   $aclassical and endemic Kaposi Sarcoma
610   $asystemic treatment
610   $amulti-state modelling
610   $atreatment free interval
610   $achemotherapy
610   $ainterferon
610   $atriple negative breast cancer
610   $aimmunomodulation
610   $abispecific antibody
610   $asortase A
610   $achemo-enzymatic approach
610   $aanti-CD20 antibody
610   $aFab
610   $aBiFab
610   $acolorectal cancer
610   $adendritic cells
610   $aAtypical Chemokine Receptor 4 (ACKR4)
610   $aT-cell priming
610   $aimmune checkpoint blockade
610   $aprimary liver cancer
610   $akynurenine pathway
610   $aimmune evasion
610   $aindoleamine 2,3 dioxygenase 1
610   $atryptophan 2,3 dioxygenase 2
610   $aIDO inhibitor
610   $aantigen presenting cells
615  7$aMedicine
700   $aSubramanian$b Subree$4edt$01289224
702   $aZhao$b Xianda$4edt
702   $aSubramanian$b Subree$4oth
702   $aZhao$b Xianda$4oth
906   $aBOOK
912   $a9910557349203321
996   $aCancer Immunology$93021107
997   $aUNINA